NCT05939596View on ClinicalTrials.gov

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 10, 2023

Primary Completion Date

September 28, 2023

Study Completion Date

August 25, 2024

Conditions
SARS-CoV-2
Interventions
BIOLOGICAL

SARS-CoV-2 Bivalent mRNA Vaccine

100 μg /1.0 mL/dose, slightly milky white and clear liquid, intramuscular injection into the lateral deltoid muscle of the upper arm.

OTHER

Saline

100 μg /1.0 mL/dose, intramuscular injection into the lateral deltoid muscle of the upper arm.

Trial Locations (1)

Unknown

First Affiliated Hospital Bengbu, Bengbu

All Listed Sponsors
collaborator

The First Affiliated Hospital of Bengbu Medical University

OTHER

lead

AIM Vaccine Co., Ltd.

INDUSTRY

NCT05939596 - A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) | Biotech Hunter | Biotech Hunter